Ocular Therapeutix Inc

NASDAQ: OCUL
$9.44
+$0.09 (+1.0%)
Closing Price on December 10, 2024

OCUL Stock Chart and Intraday Price

OCUL Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 24 CROSBY DRIVE, BEDFORD, MA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 1,234.52M USD
Shares Outstanding 114,839,000
Ocular Therapeutix Inc is a pioneering biopharmaceutical firm dedicated to innovating eye care. Using its unique bioresorbable hydrogel technology, it develops treatments for various eye conditions. Its products include ReSure Sealant for cataract surgery recovery and DEXTENZA for post-surgical pain and inflammation, alongside treatments for allergic conjunctivitis. The company is also advancing research in therapies for age-related macular degeneration, glaucoma, and dry eye disease, with several products in clinical trials. Ocular Therapeutix collaborates with industry leaders like Regeneron Pharmaceuticals to enhance retinal disease treatments, marking its commitment to improving ocular health.

OCUL Articles

With a market rotation underway, where should investors seeking opportunities in health care be looking? Analysts have high expectations for Alphatec.
Warren Buffett's Berkshire Hathaway has again bolstered its stake in Occidental Petroleum, and action at Dollar Tree also highlights recent insider buying.